Prevalence of HLA-B*5701 in HIV-infected patients in Spain (results of the EPI Study)

HIV Clin Trials. 2009 Jan-Feb;10(1):48-51. doi: 10.1310/hct1001-048.

Abstract

Background: A hypersensitivity reaction (HSR) is associated with abacavir (ABC), a nucleoside reverse transcriptase inhibitor. Genetic association of ABC HSR with the presence of HLA-B*5701 has been demonstrated in PREDICT-1 study, showing a prevalence of 5.6% in HIV-infected population. However the prevalence of this allele in HIV-infected patients in Spain has not been established yet.

Method: This is a cross-sectional epidemiological study that included 1,198 patients in 74 centers that serve the HIV-infected population of Spain. HLA-B*5701 was checked both in the hospital lab and one central lab, showing an overall prevalence of this allele of 6%.

Results: HLA-B*5701 was most prevalent in Caucasian population (6.5%). Concordance between the local and central lab was very high for positive and negative results (95.7% and 99.3%, respectively).

Conclusion: These aspects define this test as a useful tool for the management of HIV-infected patients.

MeSH terms

  • Adult
  • Aged
  • Cross-Sectional Studies
  • Dideoxynucleosides / adverse effects*
  • Dideoxynucleosides / therapeutic use
  • Drug Hypersensitivity / epidemiology
  • Drug Hypersensitivity / genetics*
  • Female
  • Genetic Testing
  • HIV Infections / drug therapy*
  • HLA-B Antigens / genetics*
  • Humans
  • Male
  • Middle Aged
  • Prevalence
  • Reverse Transcriptase Inhibitors / adverse effects*
  • Reverse Transcriptase Inhibitors / therapeutic use
  • Spain / epidemiology

Substances

  • Dideoxynucleosides
  • HLA-B Antigens
  • HLA-B*57:01 antigen
  • Reverse Transcriptase Inhibitors
  • abacavir